Given the lack of benefit of traditional cytotoxic therapy in the metastatic setting, mTOR inhibition in the setting of a clinical trial should be strongly considered in any patient with recurrent or metastatic disease. The gene discussed is MTOR; the disease is metastatic neoplasm.